Filana Therapeutics presents TSC-related epilepsy program at Eilat XVIII conference
PUBT · 05/05 12:03
Share
Listen to the news
- Filana Therapeutics presented its TSC-related epilepsy program at Eilat XVIII, antiepileptic drugs and devices conference in Madrid.
- Presentation outlined biological rationale for clinical development evaluating simufilam in TSC-related epilepsy, with work continuing to address FDA clinical hold issued in December 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050800PRIMZONEFULLFEED9713002) on May 05, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending